-+ 0.00%
-+ 0.00%
-+ 0.00%

HEMAB THERAPEUTICS - TRIAL DESIGN INCLUDES 24-WEEK RUN-IN, 48-WEEK TREATMENT; PRIMARY ENDPOINT IS ANNUALIZED TREATED BLEED RATE

Reuters·11/09/2026 12:00:01

Please log in to view news